Immunotherapy Fits Everyone? Prognostic Markers for Immune-checkpoint-Inhibitor (ICI) in Non-small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Baptista De Almeida, S. [1 ]
Caleca, T. [1 ]
Silva, M. [1 ]
Honorio, M. [1 ]
Chaves, A. [1 ]
机构：
[1] Hosp Prof Doutor Fernando Fonseca, Med Oncol, Amadora, Portugal
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
immune-checkpoint-inhibitor; prognostic markers; non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P57.01
引用
收藏
页码：S1136 / S1136
页数：1
相关论文
共 50 条
  • [21] Non-small cell lung cancer (NSCLC) predictors of response to immunotherapy (ICI): LIPI index and immune-related toxicity
    Pellitero, A. Moratiel
    Lastra, R.
    Garcia, M. Zapata
    Berjaga, M. Zurera
    Moreno, I. Ruiz
    Gomez, A. Goas
    Pi, M. Marti
    Monleon, A. Romero
    Osorio, K.
    Velasco, M. Arribas
    Per, S. Esteras
    Ruiz, M. Gascon
    Goni, A. Sesma
    Bielsa, E. Quilez
    Casado, M. D. Isla
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S83 - S83
  • [22] Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer Benefits and Pulmonary Toxicities
    Suresh, Karthik
    Naidoo, Jarushka
    Lin, Cheng Ting
    Danoff, Sonye
    CHEST, 2018, 154 (06) : 1416 - 1423
  • [23] Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
    Giustini, Nicholas
    Bazhenova, Lyudmila
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 21 - 34
  • [24] Prognostic Immune Markers in Non-Small Cell Lung Cancer-Letter
    Pandey, Janardan P.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7835 - 7835
  • [25] Prognostic Immune Markers in Non-Small Cell Lung Cancer-Response
    Suzuki, Kei
    Adusumilli, Prasad S.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7836 - 7836
  • [26] The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients
    Mezquita, L.
    Auclin, E.
    Charrier, M.
    Ferrara, R.
    Masip, J. Remon
    Planchard, D.
    Aix, S. Ponce
    Paz-Ares, L.
    Lahmar, J.
    Leroy, L.
    Audigier-Valette, C.
    Cuairan, J. Zeron-Medina
    Lopez, P. Garrido
    Brosseau, S.
    Mazieres, J.
    Caramella, C.
    Adam, J.
    Chaput, N.
    Soria, J-C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Impact of Mutation Class and Smoking Status in BRAFMutant Non-Small Cell Lung Cancer (NSCLC) Treated with Immune Checkpoint Inhibitors (ICI)
    Marin-Acevedo, J. A.
    Bandikatla, S. V.
    Thapa, R.
    Puri, S.
    Chen, D. -T.
    Hicks, K.
    Gray, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S259 - S260
  • [28] Utilization patterns of immune checkpoint inhibitors (ICI) for non-small cell lung cancer (NSCLC) within the veterans health administration (VHA).
    Moghanaki, Drew
    Jiang, Renjin
    Gutman, David
    Burns, Abigail
    Sukhatme, Vidula
    Stokes, William
    Ramalingam, Suresh S.
    Sukhatme, Vikas
    Behera, Madhusmita
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] The incidence and predictive factors of hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI).
    Lee, Yeun Ho
    Kim, Hyeonseon
    Chung, Il-Young
    Song, Chiwoo
    Kim, Leeseul
    Choi, Horyun
    Kim, Jinah
    Oh, Youjin
    Lee, Grace Yujin
    Cho, Heayoon
    Chae, Young Kwang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] The incidence and risk factors of hyperprogressive disease(HPD) in non-small cell lung cancer(NSCLC) treated with immune checkpoint inhibitors(ICI)
    Kim, Hyeonseon
    Lee, Yeun Ho
    Song, Chiwoo
    Kim, Leeseul
    Kim, Min Jeong
    Choi, Horyun
    Kim, Jinah
    Chae, Young Kwang
    CANCER RESEARCH, 2022, 82 (12)
12345